In a trial emulation using UK primary care electronic health records from 62,503 adults with type 2 diabetes who initiated empagliflozin or dipeptidyl peptidase-4 inhibitors between 2014 and 2022, researchers found that most empagliflozin users (83.2%) would not have met the eligibility criteria of the original EMPA-REG randomized trial. Empagliflozin use was associated with lower all-cause mortality compared with DPP-4 inhibitors, with consistent benefits in both randomized trial–eligible and trial-ineligible populations, supporting broader real-world use of the drug in type 2 diabetes management.

Source: BMJ Open Diabetes Research & Care